Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Wegovy is semaglutide at higher doses than Ozempic, titrated more slowly through an extra dose step at 1.7 mg
- The full titration to the 2.4 mg maintenance dose takes 17 weeks under the standard schedule
- STEP 1 showed mean weight loss accelerating from week 4 through approximately week 60, with most patients reaching their plateau between month 12 and month 14
- Subjective appetite reduction typically appears between weeks 1 and 6, well before measurable weight loss
- Wegovy is approved as a chronic medication; STEP 4 data demonstrated substantial weight regain after discontinuation, supporting long-term use when tolerated
Direct answer
Wegovy starts working subjectively within 1 to 4 weeks for most patients, with appetite reduction often noticeable before scale movement. Weight loss begins between weeks 2 and 4 and accelerates through the titration period. The STEP 1 trial showed mean weight loss of 14.9 percent over 68 weeks at the 2.4 mg maintenance dose, with most of the loss occurring between weeks 8 and 60. Reaching maintenance dose takes 17 weeks under the standard titration schedule.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Table of contents
- Why Wegovy titration is slower than Ozempic
- Week-by-week through titration
- The 2.4 mg dose: where most of the effect lives
- The STEP 1 trial curve, decoded
- Subjective response versus measured response
- Plateau, regain, and the chronic-medication framing
- Comparing Wegovy onset to Zepbound onset
- When response is faster than typical
- When response is slower than typical
- Decision framework: titration pace
- Alternative view: maybe a 17-week titration is too cautious
- FAQ
- Sources
Why Wegovy titration is slower than Ozempic
Wegovy reaches a higher final dose than Ozempic. The Wegovy maintenance dose is 2.4 mg weekly. The Ozempic maximum is 2.0 mg. Wegovy includes a 1.7 mg intermediate step that Ozempic does not.
Higher doses produce more gastrointestinal side effects at any given titration pace. The STEP 1 study used a 16-week titration to reach 2.4 mg specifically to manage this. Real-world prescribing typically follows the same pace, sometimes with extra time at problematic doses if a patient struggles with nausea.
The slower climb means the full effect of Wegovy is not visible until later in treatment than the full effect of Ozempic. A patient at week 12 of Wegovy may still be at 1 mg or 1.7 mg, while a patient at week 12 of Ozempic may already be at 1 mg or 2 mg.
Week-by-week through titration
| Weeks | Dose | What's typical |
|---|---|---|
| 1-4 | 0.25 mg | Mild appetite change for some; minimal scale movement; nausea possible in days 1-3 after each injection |
| 5-8 | 0.5 mg | Clearer appetite shift for most; some weight loss begins; reduced food noise reported |
| 9-12 | 1 mg | Steady weight loss in responders; appetite suppression typically pronounced |
| 13-16 | 1.7 mg | Further weight loss; intermediate dose unique to Wegovy |
| 17 onward | 2.4 mg | Maintenance dose; full therapeutic effect; continued weight loss through approximately week 60 |
Each step requires at least 4 weeks at the prior dose. Patients with significant side effects at any step typically pause and re-attempt the climb after 2 to 4 extra weeks of adaptation.
The 2.4 mg dose: where most of the effect lives
The 2.4 mg dose is the formulation that distinguishes Wegovy from Ozempic clinically. Below 2.4 mg, Wegovy is essentially Ozempic with a different label. At 2.4 mg, the drug pushes appetite suppression further than the Ozempic ceiling allows.
STEP 1 data showed weight loss continuing to accumulate after patients reached 2.4 mg at week 17. From week 17 to week 60, mean weight loss accumulated by an additional 8 to 10 percent. The first 17 weeks of titration produced approximately 5 to 6 percent loss; the maintenance phase produced the rest.
This is why early evaluation of Wegovy at month 3 or 4 is often misleading. The patient may have lost only 5 percent of body weight at that point, which is real but not representative of where the curve is heading. The full trial outcome belongs to patients who sat at 2.4 mg for many months.
The STEP 1 trial curve, decoded
STEP 1 (Wilding et al., NEJM 2021) enrolled 1,961 adults with obesity (BMI 30+) or overweight (BMI 27+ with comorbidities). Patients received semaglutide 2.4 mg or placebo, both with lifestyle support, over 68 weeks. Mean weight loss by week:
| Week | Wegovy arm | Placebo arm | Difference |
|---|---|---|---|
| 4 | ~2% | ~0.5% | 1.5 pp |
| 12 | ~5% | ~1% | 4 pp |
| 20 | ~8% | ~1.5% | 6.5 pp |
| 28 | ~11% | ~2% | 9 pp |
| 44 | ~13% | ~2% | 11 pp |
| 60 | ~14.5% | ~2.4% | 12.1 pp |
| 68 | ~14.9% | ~2.4% | 12.5 pp |
The shape of the curve matters. The Wegovy arm gained most of its weight loss between weeks 4 and 60. The placebo arm gained almost all of its modest loss in the first 12 weeks (likely reflecting behavioral changes from study enrollment) and then stayed flat. The divergence widens steadily across the entire trial.
Subjective response versus measured response
Patient-reported timelines often differ from scale-measured timelines.
Subjective appetite reduction often appears before the scale moves. Patients describe forgetting to eat, eating less, feeling satisfied with smaller portions. These changes precede measurable weight loss by 1 to 3 weeks because caloric deficit accumulates before it shows up as kilograms.
Subjective "feeling smaller" often lags the scale. Patients may have lost 5 percent of body weight without feeling visibly different in the mirror. The face often changes first; the abdomen and waist follow. Other people's comments typically arrive around month 3 to 4.
Subjective effort drops over time. Many patients describe weight loss on Wegovy as easier than prior dieting attempts because the appetite suppression makes caloric deficit feel less like deprivation. This is the mechanism that makes the medication clinically distinctive.
Plateau, regain, and the chronic-medication framing
The STEP 1 trial showed mean weight loss approaching plateau around weeks 56 to 60. Patients who continued the drug maintained their loss. Patients in STEP 4 (Rubino et al., JAMA 2021) who switched to placebo at week 20 regained approximately two-thirds of their lost weight over the following 48 weeks.
This is the central practical fact about Wegovy: it is not a course of treatment that ends with weight loss locked in. It is a chronic medication, like blood pressure medication, that maintains its effect as long as it is taken.
The reasons for regain on discontinuation are partly physiologic (return of appetite, metabolic adaptations from prior weight loss) and partly behavioral (return to prior eating patterns once the appetite suppression is gone). Both contribute.
Comparing Wegovy onset to Zepbound onset
| Metric | Wegovy 2.4 mg | Zepbound 15 mg |
|---|---|---|
| First subjective appetite drop | Week 1-4 | Week 1-3 |
| Time to maintenance dose | 17 weeks | 21 weeks (15 mg) |
| 4-week mean weight loss | ~2% | ~3% |
| 24-week mean weight loss | ~10% | ~15% |
| Final trial mean | 14.9% at 68 wk | 22.5% at 72 wk |
| Mechanism | GLP-1 only | GLP-1 + GIP |
The two drugs follow similar early curves. The divergence appears in the maintenance phase. Patients on Zepbound at the highest dose tend to lose more weight on average; patients on Wegovy may tolerate the drug better at the comparable response level.
When response is faster than typical
Some patients describe substantial appetite suppression at 0.25 mg in the first week. The mechanism is unclear but likely involves individual variation in central GLP-1 receptor density and signaling.
Faster-than-typical early weight loss often reflects water shifts (glycogen-bound water released as carbohydrate intake falls) more than fat loss. A 5 to 8 pound drop in the first month is common for tolerant responders, but typically half to two-thirds of that is fluid, not adipose tissue.
Strong responders exist at every dose. The STEP 1 supplementary data shows the top quartile of responders losing 20 to 25 percent body weight at trial endpoint, well above the 14.9 percent mean.
When response is slower than typical
About 15 to 30 percent of patients show limited weight response to semaglutide despite adequate dose and adherence. Wegovy at 2.4 mg is unlikely to overcome non-response that was present at lower doses; what 2.4 mg does for non-responders is mostly amplify side effects without much added benefit.
Non-responders typically have better outcomes on tirzepatide. SURPASS-2 and observational data suggest tirzepatide produces meaningful response in many semaglutide non-responders, likely because the dual GIP/GLP-1 agonism engages a different pathway.
Decision framework: titration pace
Standard pace works for most patients. Climbing every 4 weeks as scheduled produces a tolerable titration with the typical side-effect profile.
Slow the pace if:
- Nausea is interfering with daily life at any given dose
- You're losing weight steadily at the current dose
- The next dose feels intimidating based on side effects at the current one
Hold at intermediate dose if:
- You're losing weight at 1 mg or 1.7 mg and approaching target
- Side effects at the current dose are tolerable but next-step increase has consistently triggered worse symptoms
- Cost or supply is a factor and the current dose is producing acceptable response
All of these are conversations with the prescriber, not unilateral patient decisions.
Alternative view: maybe a 17-week titration is too cautious
The standard titration was designed for the average patient in the STEP 1 trial population, balancing efficacy and tolerability. It is conservative.
Many patients tolerate faster increases without significant side effects. Some clinicians use shorter titrations (2 to 3 weeks per step) for patients with mild or absent early symptoms, accelerating time to the 2.4 mg dose.
The argument for faster titration: time at sub-therapeutic doses delays clinical benefit. A patient who could have reached 2.4 mg at week 10 instead of week 17 has seven extra weeks of effective treatment.
The counterargument: faster titration produces more discontinuations and worse persistence on the drug long-term. The cumulative weight loss outcome is better for patients who titrate slowly and stay on the drug than for those who titrate fast and quit.
This is a clinical philosophy debate, not a settled question. Most prescribers default to the standard schedule and adjust based on individual response.
FAQ
What is the short answer for How Long Does It Take for Wegovy to Work? Mapping the STEP 1 Curve to Your Calendar?
Wegovy starts working subjectively within 1 to 4 weeks for most patients, with appetite reduction often noticeable before scale movement. Weight loss begins between weeks 2 and 4 and accelerates through the titration period. The STEP 1 trial showed mean weight loss of 14.9 percent over 68 weeks at the 2.4 mg maintenance dose, with most of the loss occurring between weeks 8 and 60. Reaching maintenance dose takes 17 weeks under the standard titration schedule.
What should patients track during the first few weeks?
Track dose date, appetite change, weight trend, nausea, bowel habits, hydration, sleep, and any symptom that changes after a dose increase.
When should the prescriber be involved?
Contact the prescribing clinician if symptoms are severe, persistent, worsening after titration, or paired with dehydration, abdominal pain, vomiting, low blood sugar, or medication-timing confusion.
Does this replace the medication label?
No. Use the FDA label, pharmacy instructions, and your prescriber's written plan first. This page explains the timing pattern behind how long does it take for wegovy to work.
Why do timelines vary between patients?
Timelines vary because dose escalation, starting weight, diabetes status, other medications, food intake, gastric emptying, and side-effect sensitivity differ from person to person.
What is the safest way to use this information?
Use it to set expectations and ask better questions, not to change a dose, skip a dose, restart after a break, or combine medications without medical guidance.
Related guides
- How Long Does Semaglutide Take to Suppress Appetite? The Hunger Curve, Week by Week
- How Long Does Wegovy Last in the Fridge? Pre-Use Shelf Life by Dose Step
- How Long Does Tirzepatide Take to Suppress Appetite? Mapping the Food Noise Drop
- Long-Term Effects of Wegovy: A Honest Read of STEP 5, SELECT, and What We Don't Yet Know
- How Long Does It Take for Ozempic to Work? The Phased Timeline
- How Long Does Ozempic Take to Work? A Week-by-Week Patient Map
Sources
- Wilding JPH, et al. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- Davies M, et al. STEP 2: Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. Lancet. 2021;397(10278):971-984.
- Wadden TA, et al. STEP 3: Semaglutide as Adjunct to Intensive Behavioral Therapy. JAMA. 2021;325(14):1403-1413.
- Rubino D, et al. STEP 4: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo. JAMA. 2021;325(14):1414-1425.
- Garvey WT, et al. STEP 5: Two-Year Continued Semaglutide. Nature Medicine. 2022;28:2083-2091.
- Lincoff AM, et al. SELECT: Semaglutide and Cardiovascular Outcomes in Obesity. N Engl J Med. 2023;389:2221-2232.
- Jastreboff AM, et al. SURMOUNT-1: Tirzepatide. N Engl J Med. 2022;387(3):205-216.
- FDA. Wegovy Prescribing Information. Updated 2024.
- FDA. Ozempic Prescribing Information. Updated 2024.
- Endocrine Society. Pharmacological Management of Obesity Guideline. 2023.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism. 2018;27(4):740-756.
- American Diabetes Association. Standards of Care in Diabetes. 2025.
Footer disclaimers
Platform Disclaimer. FormBlends operates as a telehealth platform that facilitates patient access to licensed clinicians. Content here is educational and is not a substitute for individualized medical evaluation, diagnosis, or treatment.
Compounded Medication Notice. Compounded semaglutide formulations available through FormBlends are prepared by 503A pharmacies. They are not FDA-approved and are not therapeutically equivalent to brand-name Wegovy or Ozempic.
Results Disclaimer. The STEP 1 curve and related trial data describe population averages under structured conditions. Individual response varies, often substantially. Real-world outcomes tend to be more modest than trial means.
Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation with these brand holders.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →